Results 61 to 70 of about 11,407 (242)
PLoS ONE, 2017 ObjectivesThis study examined gastroenterologists' motivation for prescribing biosimilars, assessed their treatment preferences in relation to prescribing behaviour, and explored patient attitudes to biosimilars.MethodsData were taken from the Adelphi ...
Emma Sullivan +4 more
doaj +1 more source
Policies for biosimilar uptake in Europe: An overview.
PLoS ONE, 2017 BackgroundAcross European countries, differences exist in biosimilar policies, leading to variations in uptake of biosimilars and divergences in savings all over Europe.ObjectivesThe aim of this article is to provide an overview of different initiatives ...
Evelien Moorkens +33 more
doaj +1 more source
Biosimilar bidding in centralized tenders in Norway
Nordic Journal of Health Economics, 2021 Our objective is to study the competition effect of biosimilar entry in centralized tenders for an expensive category or drugs - TNF-inhibitors. We use monthly observations of prices and volumes for all brands and biosimilars in this drug category in ...
Dag Morten Dalen +2 more
doaj +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Biologic therapies are a major and growing driver of pharmaceutical expenditure globally, with tumor necrosis factor (TNF) inhibitors among the most widely used and costly biologics. In Australia, these therapies are funded through the Pharmaceutical Benefits Scheme (PBS), where biosimilars offer lower cost alternatives; however, the long‐term public ...
Chin Hang Yiu +4 more
wiley +1 more source
Frontiers in Pharmacology, 2022 Background: The level of competition achieved following biosimilars market availability varies by country, care setting and molecule. Hence, biosimilars contribution to attaining price reductions and extended access to treatments can also vary.Objective:
Teresa Barcina Lacosta +4 more
doaj +1 more source
Advances in Dermatology and Allergology, 2015 Over the last decade the availability of biological drugs for the treatment of psoriasis vulgaris, psoriatic arthritis and many other inflammatory diseases has revolutionized the treatment of these diseases around the world. Due to the high cost of therapy, the search has started for biosimilars.
Mazur, Małgorzata +4 more
openaire +2 more sources
European Policy Analysis, EarlyView.ABSTRACT Policy process research has excelled in explaining structural policy change within national settings, but extensions and applications to the EU level have long proven challenging for scholars. Given that the EU is currently experiencing its longest period of Treaty stability since the 1980s—having evolved into a sui generis political system ...
Vassilis Karokis‐Mavrikos
wiley +1 more source
The Laryngoscope, EarlyView.ABSTRACT Objective With regulatory approval of HPV‐specific immunotherapy for recurrent respiratory papillomatosis (RRP) and growing experience with systemic bevacizumab, a management algorithm incorporating these medical treatments is warranted. Data Sources and Methods RRP Foundation (RRPF) Key Opinion Leaders offer a proposed management algorithm ...
Simon R. Best +17 more
wiley +1 more source
BMC Health Services Research, 2023 Background Knowledge, attitudes and substitution laws of biosimilars are not consistent across countries. Biosimilar acceptance among patients and healthcare professionals may be suffering from gaps in knowledge and understanding about biosimilars and ...
Kirstin Messner +4 more
doaj +1 more source
Biosimilarity assessment of biosimilar therapeutic monoclonal antibodies
Drug Metabolism and Pharmacokinetics, 2019 The concept of biosimilar was established in the early 2000s in EU. Currently, the regulatory framework for biosimilar has also been established in the US, Japan, and other countries. As of 2018, biosimilars for infliximab, adalimumab, rituximab, trastuzumab, and bevacizumab have been approved.
Akiko, Ishii-Watabe, Takashi, Kuwabara
openaire +2 more sources